REGULATED PRESS RELEASE published on 04/28/2025 at 18:10, 1 year 1 month ago Rapport annuel 2024 - DPEF
BRIEF published on 04/02/2025 at 18:10, 1 year 2 months ago EXACOMPTA CLAIREFONTAINE publie ses résultats financiers 2024 Baisse Des Revenus Résultats Financiers 2024 Conditions Du Marché Perspectives 2025 Performance Du Segment
BRIEF published on 04/02/2025 at 18:10, 1 year 2 months ago EXACOMPTA CLAIREFONTAINE Reports 2024 Financial Results Market Conditions Revenue Decline Segment Performance Financial Results 2024 2025 Outlook
REGULATED PRESS RELEASE published on 04/02/2025 at 18:05, 1 year 2 months ago Financial statements - 31 december 2024 EXACOMPTA CLAIREFONTAINE Board of Directors approved 2024 financial statements. Revenue: €831,274,000. Outlook cautious due to weak Q1 2025 demand Financial Statements Revenue Outlook 2024 Exacompta Clairefontaine
BRIEF published on 03/27/2025 at 18:05, 1 year 2 months ago EXACOMPTA CLAIREFONTAINE: 2024 annual results and 2025 outlook Stationery Market 2024 Results Outlook 2025 Dividend Share Paper Production
BRIEF published on 03/27/2025 at 18:05, 1 year 2 months ago EXACOMPTA CLAIREFONTAINE : Résultats annuels 2024 et perspectives 2025 Résultats 2024 Marché De La Papeterie Perspectives 2025 Production De Papier Dividende Action
REGULATED PRESS RELEASE published on 03/27/2025 at 18:00, 1 year 2 months ago Arrêté des comptes au 31 décembre 2024 et perspectives 2025 Réunion du conseil d'administration d'EXACOMPTA CLAIREFONTAINE le 27 mars 2025 à Paris pour examen des comptes 2024 et perspectives 2025 Conseil D'administration Résultats 2024 Exacompta Clairefontaine Réunion Perspectives 2025
BRIEF published on 03/03/2025 at 18:05, 1 year 3 months ago Voting Rights and Shares 2024: Exacompta Clairefontaine Report Share Capital Voting Rights Actions Financial Market Exacompta Clairefontaine
BRIEF published on 03/03/2025 at 18:05, 1 year 3 months ago Droits de Vote et Actions 2024 : Bilan d'Exacompta Clairefontaine Marché Financier Droits De Vote Capital Social Actions Exacompta Clairefontaine
REGULATED PRESS RELEASE published on 03/03/2025 at 18:00, 1 year 3 months ago Droits de vote et actions 2024 EXACOMPTA CLAIREFONTAINE déclare le nombre total de droits de vote et d’actions composant son capital pour l'année 2024 Capital Droits De Vote Actions 2024 Exacompta Clairefontaine
Published on 06/26/2026 at 01:40, 9 hours 44 minutes ago UraniumX Announces DTC Eligibility for U.S. Traded Shares
Published on 06/25/2026 at 23:30, 11 hours 54 minutes ago Zeus North America Mining Corp. Signs Option Agreement to Acquire Mining Claims in Idaho
Published on 06/25/2026 at 22:30, 12 hours 54 minutes ago Fountain Asset Corp. Provides Corporate Update
Published on 06/25/2026 at 21:32, 13 hours 52 minutes ago BlackBerry Announces Election Results for the Company's Board of Directors
Published on 06/25/2026 at 15:30, 19 hours 54 minutes ago Silver Spruce Resources, Inc. Adds Mining, Energy, and Finance Development Expertise to the Board and Announces Director Resignation
Published on 06/26/2026 at 11:14, 9 minutes ago EQS-Adhoc: Evonik Industries AG: Current financial and forecast data for the second quarter of 2026 and adjustment of the outlook for the financial year 2026
Published on 06/26/2026 at 11:05, 19 minutes ago Join the Beautiful Game: Discover Immersive Fan Experiences with Hisense at FIFA World Cup 2026™
Published on 06/26/2026 at 10:59, 25 minutes ago HELIOS SOLAR AG starts subscription period for Initial Public Offering – shares offered at EUR 4.00
Published on 06/26/2026 at 10:50, 34 minutes ago Indotek Group acquires remaining 53% stake in Auchan Hungary, assumes full ownership
Published on 06/26/2026 at 10:47, 37 minutes ago flatexDEGIRO accelerates its growth trajectory and expects to achieve its 2027 financial targets already in 2026, one year ahead of schedule
Published on 06/26/2026 at 07:00, 4 hours 24 minutes ago Advancing Women’s Health with Rapid Diagnostics: bioMérieux files a Dual 510(k) /CLIA Waiver application to the FDA for the BIOFIRE® SPOTFIRE® Vaginitis Panel
Published on 06/26/2026 at 07:00, 4 hours 24 minutes ago Améliorer la santé des femmes grâce au diagnostic rapide : bioMérieux dépose auprès de la FDA une demande combinée d’autorisation 510(k) et de dérogation CLIA pour son test BIOFIRE® SPOTFIRE® Vaginitis Panel
Published on 06/25/2026 at 18:45, 16 hours 39 minutes ago Avis Financier Semestriel SFCMC au 30 avril 2026
Published on 06/25/2026 at 18:30, 16 hours 54 minutes ago Avis financier semestriel SIEHM au 30 avril 2026
Published on 06/25/2026 at 17:50, 17 hours 34 minutes ago DISCLOSURE OF SHARE CAPITAL AND VOTING RIGHTS
